Linus Health Unveils New Dementia Risk Assessments at Global Conference

Linus Health Unveils Groundbreaking Findings on Dementia Risk Assessments

Linus Health is making headlines as it prepares to present its transformative research on digital risk scores related to dementia at the prestigious International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026). This significant event is scheduled to take place from March 17 to 21, 2026, in Copenhagen, Denmark, alongside online participation. The conference gathers thousands of experts in the field, including scientists, clinicians, and industry leaders, who are eager to exchange insights and innovations pertinent to dementia research.

Key Research Highlights

Linus Health's research showcases how advanced digital cognitive assessments can revolutionize patient identification for emerging therapies as well as the measurement of treatment impacts that align with patients' personal priorities. The presentations will consist of three key poster sessions that underline the expanding value of multimodal digital evaluations in the realm of Alzheimer's disease and related disorders.

Identifying Candidates for Treatment

One of the major focuses will be how to identify individuals most likely to benefit from disease-modifying therapies. Under the guidance of Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health, the findings indicate an innovative machine-learning approach through the Digital Clock and Recall (DCR™) model. The poster, titled "Identifying Eligible Candidates for Alzheimer's Disease Modifying Treatment with the Digital Clock and Recall (DCR™)," demonstrates a high efficiency in recognizing individuals in the early symptomatic stages of Alzheimer's, highlighting a cognitive score that can potentially narrow down effective candidates for ongoing research.

The second poster, "Prediction of Plasma p-tau217 Status and Alzheimer's Risk with the Remote Ready Digital Assessment of Cognition," illustrates how Linus Health's methodology presents scalable predictions that support both preliminary and community screenings for Alzheimer’s risk. It emphasizes how accurate and predictive it is in prioritizing necessary confirmatory tests, eliminating superfluous biomarker evaluations.

“As digital assessments gain traction, they are increasingly pivotal in discerning, stratifying participants for Alzheimer’s research,” stated Jannati, stressing the importance of integrating high-resolution cognitive evaluations with risk-derived biomarkers like amyloid-PET and plasma p-tau217. This combination enables a more efficient pathway to reach trial-ready candidates.

Participant-Centered Outcomes

Stina Saunders, PhD, Personalized Medicine Lead at Linus Health, will present research on integrating culturally responsive and person-specific outcome measures in international contexts. Her study, titled "A Feasibility Study to Assess the Applicability and User Acceptance of the Electronic Person Specific Outcome Measures (ePSOM) in a Japanese Memory Clinic Population," examines how this innovative digital tool can capture what is most important to patients in their everyday lives, gauging their confidence in maintaining these priorities over time.

The findings are built upon previous results from the UK and US, advancing the methodology on how personalized evaluations can be implemented broadly in international research settings. As Saunders remarked, "With the emergence of novel Alzheimer's treatments, it is crucial that study endpoints reflect the participants’ perspective across various cultures, ensuring their priorities are central to the research."

A Multimodal Approach

In addition to these compelling findings, Linus Health intends to showcase its comprehensive multimodal platform that combines cognitive, speech, and motor assessments aimed at addressing not just Alzheimer’s but other neurodegenerative diseases like Parkinson’s. By harnessing an array of data sources, this platform enables life sciences organizations to find suitable participants for clinical trials while creating composite digital endpoints that facilitate early detection, precise candidate stratification, and gameplay for longitudinal tracking through various disease stages.

Conference attendees are encouraged to visit the Linus Health booth and arrange meetings to delve deeper into these innovative approaches to advancing brain health.

About Linus Health

Linus Health, headquartered in Boston, is at the forefront of digital health innovation, committed to reshaping brain health for people globally. By leveraging the latest in neuroscience, clinical expertise, and artificial intelligence, Linus Health aims to foster a future where cognitive and brain disorders are detected and addressed timely, allowing individuals to lead longer, healthier lives. Their digital cognitive assessment platform is a step toward practical solutions for proactive brain health management, empowering healthcare professionals and researchers with insightful, actionable data.

To explore more about Linus Health's cutting-edge methods and commitment to brain health, please visit www.linushealth.com or connect with them on LinkedIn.